10 Best Multibagger Penny Stocks of 2025

2. AbCellera Biologics Inc. (NASDAQ:ABCL)

Share Price as of August 29: $2.5

Average Upside Potential as of August 29: 329.7%

Number of Hedge Fund Holders: 16

AbCellera Biologics Inc. (NASDAQ:ABCL) is a healthcare company based in Vancouver, Canada. The company builds an engine for antibody drug discovery and development which discovers antibodies from natural immune responses.

The main reason to buy AbCellera Biologics Inc. (NASDAQ:ABCL) right now is that it has been developing its business rigorously enough to initiate 90 programs with downstream revenue potential by this March. Analysts covering the stock believe its revenue can rise significantly over the coming years. The company is also incredibly liquid. In its second-quarter earnings call, it was noted that AbCellera Biologics Inc. (NASDAQ:ABCL) still has about $700 million in cash and equivalents and approximately $220 million in available government funding to help it execute its programs and operations.

One thing to worry about, though, is AbCellera Biologics Inc.’s (NASDAQ:ABCL) cash burn. In the second quarter, the company’s revenue was $7 million, while its R&D expenses for the quarter were $41 million. Some investors may see this as a cause for concern, but seeing as the company overall ended the quarter with $698 million in cash, equivalents, and marketable security, there does seem to be room for AbCellera Biologics Inc. (NASDAQ:ABCL) to continue its current pace of cash burn for a few more years before it needs to raise more capital. All in all, this biotech penny stock is definitely a risky play, but judging by its upside potential, it may be worth the risk.

There were 16 hedge funds long AbCellera Biologics Inc. (NASDAQ:ABCL) in the second quarter, with a total stake value of $122.2 million.